Treatment

Evidence-Based Practices Resource Center

SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders. This new Evidence-Based Practices Resource Center aims to provide communities, clinicians, policy-makers and others in the field with the information and tools they need to incorporate evidence-based practices into their communities or clinical settings. The Resource Center contains a collection of scientifically-based resources for a broad range of audiences, including Treatment Improvement Protocols, toolkits, resource guides, clinical practice

Mindfulness-Oriented Recovery Enhancement Remediates Hedonic Dysregulation in Opioid Users: Neural and Affective Evidence of Target Engagement

Citation
Garland, E. L., Atchley, R. M., Hanley, A. W., Zubieta, J. K., & Froeliger, B. (2019). Mindfulness-Oriented Recovery Enhancement remediates hedonic dysregulation in opioid users: Neural and affective evidence of target engagement. Science advances, 5(10), eaax1569.
Publication Date

Abstract

Addiction neuroscience models posit that recurrent drug use increases reactivity to drug-related cues and blunts responsiveness to natural rewards, propelling a cycle of hedonic dysregulation that drives addictive behavior.

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial

Citation
Lintzeris N, Dunlop AJ, Haber PS, et al. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(5):e219041. doi:10.1001/jamanetworkopen.2021.9041
Publication Date

Abstract

Importance: Patient-reported outcomes in the treatment of opioid dependence may differ between subcutaneously administered depot buprenorphine and daily sublingual buprenorphine.

Objective: To compare patient satisfaction between depot buprenorphine and sublingual buprenorphine in adult outpatients with opioid dependence.

NAADAC Advancing Awareness in LGBTQ Care Series

Advancing Awareness in LGBTQ Care, Part I: History of Specialized Treatment for LGTBQ+ Clients Friday, June 18, 2021 @ 12:00-2:00pm ET Earn 2 CEs Register Now Advancing Awareness in LGBTQ Care, Part II: LGBTQ Youth, Community & Alcohol Misuse Friday, July 16, 2021 @ 12:00-1:30pm ET Earn 1.5 CEs Register Now Advancing Awareness in LGBTQ Care, Part III: Working with LGBTQ2S+ Native American Clients Friday, August 20, 2021 @ 12:00-1:30pm ET Earn 1.5 CEs Register